First PREMIER Bank cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 27.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 607 shares of the medical instruments supplier’s stock after selling 232 shares during the period. First PREMIER Bank’s holdings in Becton, Dickinson and were worth $118,000 as of its most recent SEC filing.
Several other hedge funds have also recently modified their holdings of BDX. North Star Investment Management Corp. raised its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares during the last quarter. Crestwood Advisors Group LLC bought a new stake in Becton, Dickinson and during the first quarter valued at about $101,000. Almanack Investment Partners LLC. bought a new stake in Becton, Dickinson and during the first quarter valued at about $105,000. Parkside Financial Bank & Trust raised its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares during the last quarter. Finally, Financial Architects Inc raised its stake in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 261 shares during the last quarter. Institutional investors own 75.57% of the company’s stock.
Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.75% during midday trading on Tuesday, hitting $200.67. The company had a trading volume of 244,468 shares. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The company has a market capitalization of $45.67 billion, a price-to-earnings ratio of 58.11 and a beta of 1.05. The company’s 50-day moving average price is $199.84 and its 200 day moving average price is $189.00.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business earned $2.35 EPS. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is 83.43%.
Several analysts recently issued reports on the company. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, July 17th. Cowen and Company reiterated a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $195.79.
In other news, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now directly owns 26,638 shares in the company, valued at approximately $5,279,917.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares of the company’s stock, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders sold a total of 57,631 shares of company stock valued at $11,112,178 over the last quarter. 1.40% of the stock is owned by company insiders.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
